Highlights from the CHMP July 2025 Meeting are out! New Medicines 💊 Servier's vorasidenib (Voranigo; IDH1/2 inhibitor) monotherapy for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy New Biosimilars 💊 Henlius' denosuma